贝伐珠单抗联合顺铂与培美曲塞治疗晚期肺癌的临床效果分析

Analysis of Clinical Effect of Bevacizumab Combined with Cisplatin and Pemetrexed in Treatment of Advanced Lung Cancer

目的:分析贝伐珠单抗联合顺铂与培美曲塞治疗晚期肺癌的临床效果。方法:选取2022年1—10月鄂尔多斯市达拉特旗人民医院呼吸与危重症医学科收治的82例肺癌患者作为研究对象,采用抽签法随机分为对照组与观察组,各41例。对照组采用顺铂与培美曲塞治疗,观察组在对照组基础上给予贝伐珠单抗治疗。比较两组疗效、用药不良反应以及肿瘤相关因子水平。结果:观察组近期有效率高于对照组,差异有统计学意义(P=0.001);两组临床获益率比较,差异无统计学意义(P>0.05)。观察组不良反应总发生率低于对照组,差异有统计学意义(P=0.023)。治疗前,两组基质金属蛋白酶2(MMP2)、肿瘤坏死因子-β1(TNF-β1)、金属肽酶组织抑制剂-1(TIMP-1)、血管内皮生长因子(VEGF)水平比较,差异无统计学意义(P>0.05);治疗后,两组MMP2、TNF-β1、TIMP-1、VEGF水平低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。结论:贝伐珠单抗联合顺铂与培美曲塞治疗晚期肺癌的临床效果显著,可提高近期疗效,降低不良反应发生率与肿瘤相关因子水平。

Objective:To analyze the clinical effect of bevacizumab combined with cisplatin and pemetrexed in the treatment of advanced lung cancer.Methods:A total of 82 lung cancer patients admitted to the Department of Respiratory and Critical Care Medicine of The People's Hospital of DaLaTe in Ordos City from January 2022 to October 2022 were selected as the study sub-jects,and they were randomly divided into control group and observation group by lot method,with 41 cases in each group.The control group was treated with cisplatin and pemetrexed,and the observation group was treated with bevacizumab on the basis of the control group.The efficacy,adverse drug reactions and levels of tumor-related factors were compared between the two groups.Results:The short-term effective rate in the observation group was higher than that in the control group,and the difference was statistically significant(P=0.001).There was no significant difference in the clinical benefit rate between the two groups(P>0.05).The total incidence of adverse reactions in the observation group was lower than that in the control group,and the difference was statistically significant(P=0.023).Before treatment,there was no significant difference in the levels of matrix metalloproteinase 2(MMP2),tumor necrosis factor-β1(TNF-β1),tissue inhibitor of metallopeptidine-1(TIMP-1)and vascular endothelial growth factor(VEGF)between the two groups(P>0.05).After treatment,the levels of MMP2,TNF-β1,TIMP-1,VEGF in the two groups were lower than those before treatment,and the levels in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05).Conclusion:Bevacizumab combined with cisplatin and pemetrexed has significant clinical effect in the treatment of advanced lung cancer,and can improve the short-term efficacy and reduce the incidence of ad-verse reactions and the levels of tumor-related factors.